MedTrace Logo

Pregabalin Versus Levetiracetam In Partial Seizures

NCT00537238 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 509

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

This study will compare pregabalin and levetiracetam in patients with partial seizures. It will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.

Conditions

  • Partial Seizures

Interventions

DRUG

pregabalin

300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects

DRUG

levetiracetam

1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Belgium
  • Bulgaria
  • Colombia
  • Costa Rica
  • Czechia
  • France
  • Germany
  • Greece
  • India
  • Italy
  • Lithuania
  • Mexico
  • Panama
  • Peru
  • Philippines
  • Russia
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • Venezuela

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00537238 on ClinicalTrials.gov